TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 22705425

Group type: EXPERIMENTAL
Intervention: INE+MNP
Number of subjects: 215

Group type: EXPERIMENTAL
Intervention: INE
Number of subjects: 215

Group type: EXPERIMENTAL
Intervention: NNE+MNP
Number of subjects: 215

Group type: EXPERIMENTAL
Intervention: NNE
Number of subjects: 215
Study: 20209088

Group type: EXPERIMENTAL
Intervention: Vitamin D (≥800 IU orally daily)
Number of subjects: 12875

Group type: EXPERIMENTAL
Intervention: Hip protectors
Number of subjects: 12875

Group type: EXPERIMENTAL
Intervention: Fluoride
Number of subjects: 12875

Group type: EXPERIMENTAL
Intervention: Sunlight exposure
Number of subjects: 12875

Group type: EXPERIMENTAL
Intervention: Exercise or multimodal interventions
Number of subjects: 12875

Group type: EXPERIMENTAL
Intervention: Alendronate
Number of subjects: 12875

Group type: EXPERIMENTAL
Intervention: Staff education and risk assessment strategy
Number of subjects: 12875
Study: 18520275

Group type: EXPERIMENTAL
Intervention: Modified forearm minidose intravenous regional anesthesia (IVRA)
Number of subjects: 62

Group type: COMPARATOR
Intervention: Conventional minidose intravenous regional anesthesia (IVRA)
Number of subjects: 62
Study: 15925082

Group type: EXPERIMENTAL
Intervention: Tadalafil 20mg on demand (maximum one dose per day before sexual activity)
Number of subjects: 4262

Group type: COMPARATOR
Intervention: Tadalafil 20mg 3 times/week
Number of subjects: 4262
Study: 12182445

Group type: EXPERIMENTAL
Intervention: GnRH antagonist
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: GnRH agonist
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Insulin
Number of subjects: 0
Study: 10496513

Group type: EXPERIMENTAL
Intervention: Transference interpretations
Number of subjects: 40
Study: 7579093

Group type: EXPERIMENTAL
Intervention: Plasma clearance of iohexol (single iv dose)
Number of subjects: 41

Group type: EXPERIMENTAL
Intervention: Plasma clearance of iohexol
Number of subjects: 41

Group type: EXPERIMENTAL
Intervention: GFR determined with iohexol
Number of subjects: 41
Study: 1782726

Group type: EXPERIMENTAL
Intervention: Oral cyclosporin A
Number of subjects: 12

Group type: COMPARATOR
Intervention: Vehicle placebo
Number of subjects: 12
Study: 7006285

Group type: EXPERIMENTAL
Intervention: 30 mg/kg of methylprednisolone
Number of subjects: 26

Group type: COMPARATOR
Intervention: Control (no methylprednisolone)
Number of subjects: 26
Study: 31166984

Group type: EXPERIMENTAL
Intervention: Male Partner Involvement (Phase 2)
Number of subjects: 1424

Group type: COMPARATOR
Intervention: No Male Partner Involvement (Phase 1)
Number of subjects: 1424
Study: 30025692

Group type: EXPERIMENTAL
Intervention: Catheter ablation with endpoint of noninducibility of VT ≥300 ms after ablation
Number of subjects: 129

Group type: COMPARATOR
Intervention: Inducible VT or inducibility testing not performed
Number of subjects: 129
Study: 26493396

Group type: EXPERIMENTAL
Intervention: Continuous caudal epidural bupivacaine 0.125 % with fentanyl, IV fentanyl, and paracetamol
Number of subjects: 60

Group type: COMPARATOR
Intervention: IV fentanyl and paracetamol
Number of subjects: 60
Study: 24574190

Group type: EXPERIMENTAL
Intervention: TMD + virgin olive oil (VOO)
Number of subjects: 930

Group type: EXPERIMENTAL
Intervention: TMD + nuts
Number of subjects: 930

Group type: COMPARATOR
Intervention: Low-fat diet (control)
Number of subjects: 930
Study: 23338262

Group type: EXPERIMENTAL
Intervention: Fortify
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Fortify Plus
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Biscover LV
Number of subjects: 40

Group type: COMPARATOR
Intervention: Control group (no surface treatment)
Number of subjects: 40
Study: 20061693

Group type: EXPERIMENTAL
Intervention: Intraluminal vancomycin (500 mg infusion via both lumens of the Permcath and antibiotic lock of 1.5 mL every 48 hours) and intravenous ceftriaxone (1 g every 12 hours for 7 days) followed by oral antibiotics for three weeks
Number of subjects: 67

Group type: COMPARATOR
Intervention: Intravenous vancomycin (500 mg) and daily intravenous amikacin (100-150 mg)
Number of subjects: 67
Study: 18834241

Group type: EXPERIMENTAL
Intervention: Periodontal therapy before 21 weeks' gestation
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group (periodontal treatment after delivery)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Periodontal therapy
Number of subjects: 0
Study: 16095436

Group type: EXPERIMENTAL
Intervention: Recruitment telephone call by a nurse quitline counselor
Number of subjects: 625

Group type: EXPERIMENTAL
Intervention: Recruitment postcard
Number of subjects: 625

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 625
Study: 11755281

Group type: EXPERIMENTAL
Intervention: Direct stenting
Number of subjects: 206

Group type: COMPARATOR
Intervention: Conventional stenting
Number of subjects: 206
Study: 9400462

Group type: EXPERIMENTAL
Intervention: 60 Gy external radiotherapy with 18 MV photon beams between 12 and 16 weeks postoperatively
Number of subjects: 100

Group type: COMPARATOR
Intervention: Surveillance (no radiotherapy)
Number of subjects: 100
Study: 7521895

Group type: EXPERIMENTAL
Intervention: Cyclosporin A (CsA) +/‐ azathioprine (n = 10)
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: FK 506 (n = 10)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Healthy control subjects (n = 10)
Number of subjects: 20
Study: 2670915

Group type: EXPERIMENTAL
Intervention: d-fenfluramine (15 mg p.o. twice daily)
Number of subjects: 18

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: d-fenfluramine
Number of subjects: 18
Study: 984522

Group type: EXPERIMENTAL
Intervention: Bisolvon intravenously
Number of subjects: 40
Study: 31828479

Group type: EXPERIMENTAL
Intervention: Prolonged phase change material (PCM) cooling
Number of subjects: 26

Group type: COMPARATOR
Intervention: Melted packs (control)
Number of subjects: 26
Study: 31808923

Group type: EXPERIMENTAL
Intervention: Glioma Index constructed using 3 microRNAs (miR-4763-3p, miR-1915-3p, and miR-3679-5p)
Number of subjects: 580

Group type: EXPERIMENTAL
Intervention: 3-Tumor Index constructed using 48 microRNAs
Number of subjects: 580
Study: 27325179

Group type: EXPERIMENTAL
Intervention: Patient-centered outcomes research involving community engagement over 18 months.
Number of subjects: 31

Group type: EXPERIMENTAL
Intervention: Community-based participatory principles in research design.
Number of subjects: 31
Study: 25825855

Group type: EXPERIMENTAL
Intervention: 2‐week multidisciplinary clinical hunger provocation program
Number of subjects: 22

Group type: COMPARATOR
Intervention: 4‐week outpatient treatment by the same multidisciplinary team
Number of subjects: 22
Study: 23006632

Group type: COMPARATOR
Intervention: Cholecystokinin (CCK) during ramp distension
Number of subjects: 44

Group type: COMPARATOR
Intervention: Cholecystokinin (CCK) during intermittent distension
Number of subjects: 44

Group type: COMPARATOR
Intervention: Placebo during ramp distension
Number of subjects: 44

Group type: COMPARATOR
Intervention: Placebo during intermittent distension
Number of subjects: 44
Study: 21764118

Group type: EXPERIMENTAL
Intervention: Sertraline (150 mg per day)
Number of subjects: 326

Group type: EXPERIMENTAL
Intervention: Mirtazapine (45 mg)
Number of subjects: 326

Group type: COMPARATOR
Intervention: Placebo (control group)
Number of subjects: 326
Study: 19517423

Group type: EXPERIMENTAL
Intervention: 75 mg venlafaxine tablets
Number of subjects: 32
Study: 17082465

Group type: EXPERIMENTAL
Intervention: Graded motor imagery (2 weeks each of limb laterality recognition, imagined movements, and mirror movements)
Number of subjects: 51

Group type: COMPARATOR
Intervention: Physical therapy and ongoing medical care (Control)
Number of subjects: 51
Study: 15022300

Group type: EXPERIMENTAL
Intervention: Energy Conservation and Activity Management (ECAM) intervention
Number of subjects: 396

Group type: COMPARATOR
Intervention: Control intervention focused on nutrition
Number of subjects: 396
Study: 11717207

Group type: EXPERIMENTAL
Intervention: Unidirectional rotation (UNI)
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Bidirectional needle rotation (BI)
Number of subjects: 60

Group type: COMPARATOR
Intervention: No rotation (NO)
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Acupuncture points
Number of subjects: 60

Group type: COMPARATOR
Intervention: Control points
Number of subjects: 60
Study: 9728903

Group type: EXPERIMENTAL
Intervention: Tianeptine
Number of subjects: 69

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 69
Study: 7991719

Group type: EXPERIMENTAL
Intervention: 3,4‐dihydroxyphenylacetic acid (DOPAC)
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: 3‐hydroxykynurenine
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: metanephrine
Number of subjects: 20

Group type: COMPARATOR
Intervention: standard dose of neuroleptic
Number of subjects: 20
Study: 2604291

Group type: EXPERIMENTAL
Intervention: Combined formulation of isoniazid (125 mg), rifampin (100 mg), and pyrazinamide (375 mg)
Number of subjects: 627

Group type: COMPARATOR
Intervention: Separate formulations of isoniazid, rifampin, and pyrazinamide
Number of subjects: 627

Group type: EXPERIMENTAL
Intervention: Combined formulation
Number of subjects: 627

Group type: COMPARATOR
Intervention: Separate formulations
Number of subjects: 627
Study: 31037783

Group type: EXPERIMENTAL
Intervention: Incidental exposure to a prototypical alcohol brand
Number of subjects: 109

Group type: EXPERIMENTAL
Intervention: Incidental exposure to a non-prototypical alcohol brand
Number of subjects: 109

Group type: EXPERIMENTAL
Intervention: Incidental exposure to a brand unrelated to alcohol
Number of subjects: 109

Group type: COMPARATOR
Intervention: Cognitively depleting task
Number of subjects: 109

Group type: COMPARATOR
Intervention: Control task
Number of subjects: 109
Study: 28765194

Group type: EXPERIMENTAL
Intervention: Green Tea Extract (GTE)
Number of subjects: 1021

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1021
Study: 26391052

Group type: EXPERIMENTAL
Intervention: Simulator-integrated tutoring
Number of subjects: 22

Group type: COMPARATOR
Intervention: Self-directed practice without tutoring
Number of subjects: 22
Study: 23271193

Group type: COMPARATOR
Intervention: Drug Effects Questionnaire (DEQ) for amphetamine
Number of subjects: 0

Group type: COMPARATOR
Intervention: Drug Effects Questionnaire (DEQ) for nicotine
Number of subjects: 0

Group type: COMPARATOR
Intervention: Drug Effects Questionnaire (DEQ) for alcohol
Number of subjects: 0
Study: 21699471

Group type: EXPERIMENTAL
Intervention: Cervical total disc replacement (CTDR) using Kineflex|C
Number of subjects: 269

Group type: COMPARATOR
Intervention: Anterior cervical discectomy and fusion (ACDF)
Number of subjects: 269
Study: 18503496

Group type: EXPERIMENTAL
Intervention: Cow's milk-based infant formula
Number of subjects: 94

Group type: COMPARATOR
Intervention: Control group (autoantibody negative subjects)
Number of subjects: 94
Study: 16835255

Group type: EXPERIMENTAL
Intervention: Intra-articular magnesium sulphate (MgSO4) 10 ml (50 mg/ml)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Normal saline 10 ml (Control Group)
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Intra-articular magnesium sulphate (MgSO4)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Normal saline (Control Group)
Number of subjects: 60
Study: 11808835

Group type: EXPERIMENTAL
Intervention: Smoking cessation
Number of subjects: 51

Group type: COMPARATOR
Intervention: Smoking reduction (4-8 cigarettes daily)
Number of subjects: 51

Group type: COMPARATOR
Intervention: Continued smoking
Number of subjects: 51
Study: 10417457

Group type: COMPARATOR
Intervention: Noncricoid pressure
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: Cricoid pressure
Number of subjects: 50
Study: 8775880

Group type: EXPERIMENTAL
Intervention: Carotid endarterectomy
Number of subjects: 0

Group type: COMPARATOR
Intervention: Standard medical therapy with aspirin
Number of subjects: 0

Group type: COMPARATOR
Intervention: Ticlopidine
Number of subjects: 0

Group type: COMPARATOR
Intervention: Novel antiplatelet and antithrombotic agents
Number of subjects: 0
Study: 2342740

Group type: EXPERIMENTAL
Intervention: Preterm birth prevention program consisting of risk scoring, intensive weekly observation including cervical examinations, and detailed education about preterm labor signs and symptoms.
Number of subjects: 1000

Group type: EXPERIMENTAL
Intervention: Preterm birth prevention program (treatment group).
Number of subjects: 1000

Group type: COMPARATOR
Intervention: Control group (not specified).
Number of subjects: 1000
Study: 7449720

Group type: EXPERIMENTAL
Intervention: Intravenous administration of Quinupramine
Number of subjects: 32

Group type: COMPARATOR
Intervention: Oral administration of Quinupramine
Number of subjects: 32
Study: 6832466

Group type: EXPERIMENTAL
Intervention: Indobufen (200 mg single oral dose)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 20
Study: 30935809

Group type: EXPERIMENTAL
Intervention: Therapeutic ultrasound (US), continuous ultrasound, intensity 1.5 w/cm2, frequency 1 MHz, duration 10 minutes
Number of subjects: 32

Group type: COMPARATOR
Intervention: Radial extracorporeal shock wave therapy (rESWT), 0.340 mJ/mm2, 2000 shots
Number of subjects: 32
Study: 29160925

Group type: EXPERIMENTAL
Intervention: Swaddled bathing (SB)
Number of subjects: 80

Group type: COMPARATOR
Intervention: Traditional tub bathing (TTB)
Number of subjects: 80
Study: 26687020

Group type: EXPERIMENTAL
Intervention: Long-wave diathermy and interferential currents (ITH)
Number of subjects: 67

Group type: COMPARATOR
Intervention: Long-wave diathermy at low power (LDL)
Number of subjects: 67
Study: 25377370

Group type: EXPERIMENTAL
Intervention: Trazodone (hypnotic doses)
Number of subjects: 50

Group type: COMPARATOR
Intervention: Zopiclone (hypnotic agent)
Number of subjects: 50
Study: 22971488

Group type: EXPERIMENTAL
Intervention: Dexmedetomidine
Number of subjects: 198

Group type: COMPARATOR
Intervention: Midazolam
Number of subjects: 198
Study: 21169106

Group type: EXPERIMENTAL
Intervention: Capsaicin
Number of subjects: 48

Group type: COMPARATOR
Intervention: Saline 0.9%
Number of subjects: 48
Study: 18946743

Group type: EXPERIMENTAL
Intervention: Cholestyramine 2 g BID, methimazole, and propranolol
Number of subjects: 45

Group type: EXPERIMENTAL
Intervention: Cholestyramine 1 g BID, methimazole, and propranolol
Number of subjects: 45

Group type: COMPARATOR
Intervention: Placebo powder, methimazole, and propranolol
Number of subjects: 45
Study: 16238900

Group type: EXPERIMENTAL
Intervention: Almotriptan 12.5 mg
Number of subjects: 221

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 221
Study: 11838627

Group type: EXPERIMENTAL
Intervention: Vitamin B6 (100 mg/day increasing to 400 mg/day over 4 weeks)
Number of subjects: 15

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 15
Study: 10217596

Group type: EXPERIMENTAL
Intervention: PncCRM
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: PncT
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: PncD
Number of subjects: 0

Group type: COMPARATOR
Intervention: PncOMPC
Number of subjects: 0
Study: 7749155

Group type: EXPERIMENTAL
Intervention: Radiotherapy of the remaining breast tissue
Number of subjects: 1036

Group type: COMPARATOR
Intervention: Mastectomy
Number of subjects: 1036
Study: 2259863

Group type: EXPERIMENTAL
Intervention: Norfloxacin 400 mg twice daily for 7 days
Number of subjects: 52

Group type: COMPARATOR
Intervention: Untreated control
Number of subjects: 52
Study: 7397630

Group type: EXPERIMENTAL
Intervention: CCNU, vinblastine, procarbazine, and prednisone (CVPP)
Number of subjects: 566

Group type: COMPARATOR
Intervention: MVPP regimen (mechlorethamine, vincristine, procarbazine, and prednisone)
Number of subjects: 566

Group type: EXPERIMENTAL
Intervention: Induction regimens containing vinblastine
Number of subjects: 566

Group type: EXPERIMENTAL
Intervention: Vinblastine with periodic reinforcement
Number of subjects: 566
Study: 27352792

Group type: EXPERIMENTAL
Intervention: Make a Move intervention
Number of subjects: 177

Group type: COMPARATOR
Intervention: Waiting list control group
Number of subjects: 177
Study: 28580654

Group type: EXPERIMENTAL
Intervention: Two-window technique
Number of subjects: 21

Group type: COMPARATOR
Intervention: Solo-window technique
Number of subjects: 21
Study: 25920468

Group type: EXPERIMENTAL
Intervention: Church-based diabetes self-management program (eight weekly group classes led by trained lay leaders)
Number of subjects: 100

Group type: COMPARATOR
Intervention: Enhanced usual care (one 90-minute lecture on diabetes self-management)
Number of subjects: 100
Study: 23630211

Group type: EXPERIMENTAL
Intervention: G‐CSF throughout all chemotherapy cycles
Number of subjects: 167

Group type: COMPARATOR
Intervention: G‐CSF during the first two cycles only
Number of subjects: 167
Study: 21271228

Group type: EXPERIMENTAL
Intervention: Ultrasound (US)
Number of subjects: 56

Group type: COMPARATOR
Intervention: Nerve stimulation (NSt)
Number of subjects: 56
Study: 19058889

Group type: EXPERIMENTAL
Intervention: S3 Bond (S3)
Number of subjects: 23

Group type: EXPERIMENTAL
Intervention: G-Bond (GB)
Number of subjects: 23
Study: 17695603

Group type: EXPERIMENTAL
Intervention: Hydrogen peroxide (HP) concentrations ranging from 15% to 35% with treatment contact times of 15 to 60 minutes.
Number of subjects: 8
Study: 15096085

Group type: EXPERIMENTAL
Intervention: Lamotrigine (50‐400 mg/day fixed dose or 100‐400 mg/day flexible dose)
Number of subjects: 638

Group type: EXPERIMENTAL
Intervention: Lithium (serum level of 0.8‐1.1 mEq/L)
Number of subjects: 638

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 638

Group type: EXPERIMENTAL
Intervention: Lamotrigine
Number of subjects: 638

Group type: EXPERIMENTAL
Intervention: Lithium
Number of subjects: 638
Study: 12017403

Group type: COMPARATOR
Intervention: Sumatriptan 50 mg alone
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Combination treatment (Sumatriptan 50 mg + Clarithromycin 500 mg)
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Both treatments (Sumatriptan alone and Combination treatment)
Number of subjects: 24
Study: 10191737

Group type: EXPERIMENTAL
Intervention: Norian SRS (injectable calcium phosphate bone cement)
Number of subjects: 40

Group type: COMPARATOR
Intervention: External fixation (Hoffman's bar)
Number of subjects: 40
Study: 7741372

Group type: EXPERIMENTAL
Intervention: Early zidovudine therapy
Number of subjects: 0

Group type: COMPARATOR
Intervention: Deferred zidovudine therapy
Number of subjects: 0
Study: 2373130

Group type: EXPERIMENTAL
Intervention: Energy deficient diet (daily energy intake 4.3 MJ; daily protein intake 0.94 g/kg)
Number of subjects: 9

Group type: EXPERIMENTAL
Intervention: Protein deficient diet (daily energy intake 11.4 MJ; daily protein intake 0.31 g/kg)
Number of subjects: 9

Group type: COMPARATOR
Intervention: Control diet (daily energy intake 12.0 MJ; daily protein intake 1.52 g/kg)
Number of subjects: 9
Study: 7032558

Group type: EXPERIMENTAL
Intervention: Controlled-release morphine tablets (MST-1; 2 x 10 mg)
Number of subjects: 28

Group type: COMPARATOR
Intervention: Oral morphine sulphate in solution (20 mg)
Number of subjects: 28

Group type: EXPERIMENTAL
Intervention: Controlled-release morphine tablets (MST-1)
Number of subjects: 28
Study: 31508861

Group type: EXPERIMENTAL
Intervention: Workshop
Number of subjects: 32

Group type: EXPERIMENTAL
Intervention: Supervision-consultation
Number of subjects: 32

Group type: EXPERIMENTAL
Intervention: External facilitation
Number of subjects: 32
Study: 29882677

Group type: EXPERIMENTAL
Intervention: app + meter
Number of subjects: 44

Group type: COMPARATOR
Intervention: meter-only
Number of subjects: 44
Study: 27107155

Group type: EXPERIMENTAL
Intervention: Acceptance and Commitment Therapy (ACT)
Number of subjects: 0
Study: 25196040

Group type: EXPERIMENTAL
Intervention: Caffeine-glucose combination (60g glucose + 40mg caffeine)
Number of subjects: 150

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 150

Group type: COMPARATOR
Intervention: 60g glucose
Number of subjects: 150

Group type: COMPARATOR
Intervention: 25g glucose
Number of subjects: 150
Study: 22120913

Group type: EXPERIMENTAL
Intervention: Chelation therapy (deferasirox)
Number of subjects: 161

Group type: COMPARATOR
Intervention: Chronic transfusion therapy
Number of subjects: 161

Group type: EXPERIMENTAL
Intervention: Monitoring of iron burden
Number of subjects: 161
Study: 21194441

Group type: EXPERIMENTAL
Intervention: Intra-articular interleukin-1 receptor antagonist (IL-1Ra) therapy
Number of subjects: 11
Study: 17428721

Group type: EXPERIMENTAL
Intervention: Cardioselective beta-blockers
Number of subjects: 40

Group type: COMPARATOR
Intervention: No beta-blockers (Control)
Number of subjects: 40
Study: 16334760

Group type: EXPERIMENTAL
Intervention: CT colonography
Number of subjects: 32

Group type: COMPARATOR
Intervention: Conventional colonoscopy
Number of subjects: 32
Study: 12488789

Group type: EXPERIMENTAL
Intervention: Fabry patients
Number of subjects: 30
Study: 9498410

Group type: EXPERIMENTAL
Intervention: FAST performed by surgery residents or attending trauma surgeons
Number of subjects: 196

Group type: EXPERIMENTAL
Intervention: FAST performed in a mean time of 3.9 minutes
Number of subjects: 196

Group type: COMPARATOR
Intervention: Patients followed up clinically without CT or surgery
Number of subjects: 196
Study: 8060251

Group type: EXPERIMENTAL
Intervention: Continuous hemofiltration (SC 0.87 ± 0.10)
Number of subjects: 10

Group type: COMPARATOR
Intervention: Hemodialysis (DC 0.74 ± 0.06)
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Continuous hemofiltration (SC 1.01 ± 0.04)
Number of subjects: 10

Group type: COMPARATOR
Intervention: Hemodialysis (DC 0.97 ± 0.04)
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Continuous hemofiltration (SC 1.01 ± 0.05)
Number of subjects: 10

Group type: COMPARATOR
Intervention: Hemodialysis (DC 1.01 ± 0.07)
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Continuous hemofiltration (SC 1.00 ± 0.09)
Number of subjects: 10

Group type: COMPARATOR
Intervention: Hemodialysis (DC 1.01 ± 0.06)
Number of subjects: 10
Study: 2564723

Group type: EXPERIMENTAL
Intervention: Terazosin monotherapy
Number of subjects: 194

Group type: EXPERIMENTAL
Intervention: Methyclothiazide (MCTZ) monotherapy
Number of subjects: 194

Group type: EXPERIMENTAL
Intervention: Terazosin/MCTZ combination therapy
Number of subjects: 194

Group type: COMPARATOR
Intervention: Combination therapy vs. monotherapy
Number of subjects: 194
Study: 28058491

Group type: EXPERIMENTAL
Intervention: Hypomethylating therapy with decitabine
Number of subjects: 87
Study: 26248593

Group type: EXPERIMENTAL
Intervention: Simeprevir (150 mg for 7 days)
Number of subjects: 2

Group type: COMPARATOR
Intervention: Simeprevir (200 mg single dose)
Number of subjects: 2

Group type: EXPERIMENTAL
Intervention: Simeprevir
Number of subjects: 2